Care China-Diabetes
NCT00938119 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1603
Last updated 2013-06-28
Summary
This multicenter, prospective, observational registry will assess efficacy and safety outcomes associated with percutaneous coronary intervention (PCI) with implantation of the CYPHER Select™+ Sirolimus-eluting Coronary Stents in Chinese diabetic patients with coronary artery disease in routine clinical practice.
Conditions
Sponsors & Collaborators
-
Johnson & Johnson Medical, China
lead INDUSTRY
Principal Investigators
-
Yang Yue Jin, MD, Phd · Cardiovascular Institute & Fu Wai Hospital
-
Lv Shu Zheng, MD · Beijing Anzhen Hospital of the Capital University of Medical Sciences
-
Chen Yun Dai, MD, Phd · Chinese PLA General Hospital
-
Wang Le feng · Beijing Chaoyang Hospital Affiliated to the Capital University of Medical Sciences
-
Gao Wei, MD, Phd · Peking University Third Hospital
-
Wang Wei Min, MD, PhD · Peking University People's Hospital
-
Huo Yong, MD, PhD · Peking University First Hospital
-
Fang Quan, MD, PhD · Peking Union Medical College Hospital
-
He Qing, MD, PhD · Beijing Hospital
-
Liu Hui Liang, MD · General Hospital of Armed Police Forces
-
Li Hui, MD · General Hospital of Daqing Oilfield
-
Chen Ji Yan, MD, PhD · Guangdong Provincial People's Hospital
-
Du Zhi Min, MD · First Affiliated Hospital, Sun Yat-Sen University
-
Hou Yu Qing, MD · Southern Medical University, China
-
Li Wei Min, MD · First Affiliated Hospital of Harbin Medical University
-
Yu Bo, MD · The Second Affiliated Hospital of Harbin Medical University
-
Fu Guo Sheng, MD · Sir Run Run Shaw Hospital Affiliated with School of Medicine,Zhejiang University
-
Wang Jian An, MD, PhD · Second Affiliated Hospital, School of Medicine, Zhejiang University
-
Zhu Jian Hua, MD · First Affiliated Hospital of Zhejiang University College of Medicine
-
Liu Bin, MD · The Second Affiliated Hospital of Jilin University
-
Cui Lian Qun, MD, PhD · Shandong Provincial Hospital
-
Zhang Zheng, MD, PhD · Lanzhou University First Hospital
-
Chen Shao Liang, MD, PhD · The First Affiliated Hospital with Nanjing Medical University
-
Xu Biao, MD · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
-
Li Lang, MD, PhD · First Affiliated Hospital of Guangxi Medical University
-
Ge Jun Bo, MD, PhD · Fudan University
-
He Ben, MD,PhD · Shanghai Jiaotong University School of Medicine affiliated Renji Hospital
-
Shen Wei Feng, MD, PhD · Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
-
Xu Ya Wei, MD, PhD · Shanghai Tenth People's Hospital of Tongji University
-
Han Ya Ling, MD, PhD · General Hospital of Shenyang Military Region
-
Pang Wen Yue, MD, PhD · Shengjing Hospital
-
Li Bao, MD,PhD · Shanxi Cardiovascular Hospital
-
Lv Ji Yuan, MD · The First Affiliated Hospital of Shanxi Medical University
-
Liu Yin, MD, PhD · Tian Jin Chest Hospital
-
Qi Xiang Qian, MD · TEDA International Cardiovascular Hospital
-
Jiang Tie Min, MD · The Affiliated Hospital of Medical College of Chinese Armed Police Forces
-
Lu Cheng Zhi, MD · Tianjin First Central Hospital
-
Huang Wei Jian, MD, PhD · First Affiliated Hospital of Wenzhou Medical University
-
Sun Ying Xian, MD · First Hospital of China Medical University
-
Li Guo Qing, MD · People's Hospital of Xinjiang Uygur Autonomous Region
-
Yuan Zu Yi, MD · The First Hospital of Xian Jiao Tong University
-
Wang Hai Chang, MD · Xijing Hospital
-
Wang Yan, MD,PhD · Zhongshan Hospital Xiamen University
-
Gao Chuan Yu, MD, PhD · Henan Provincial People's Hospital
-
Wang Chun, MD, PhD · Peking University, Shen Zhen Hospital
-
Yong Wang, MD, PhD · China-Japan Friendship Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-08-31
- Primary Completion
- 2011-11-30
- Completion
- 2012-12-31
Countries
- China
Study Locations
More Related Trials
-
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial
NCT00497172 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of Intracranial Self-expanding DES in Symptomatic Intracranial Atherosclerotic Disease
NCT05217459 ·Status: COMPLETED ·Phase: NA
-
A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization
NCT01157455 ·Status: UNKNOWN ·Phase: PHASE4
-
RESOLUTE China Registry:
NCT01243749 ·Status: COMPLETED
-
China Endeavor Registry: A Registry With The Endeavor Zotarolimus Eluting Coronary Stent in China
NCT00793312 ·Status: COMPLETED
-
Coronary Covered Stents Implantation for the Treatment of Coronary Artery Perforation
NCT05398991 ·Status: RECRUITING ·Phase: NA
-
Drug-coated Balloons and Drug-eluting Stents in Diabetic Patients
NCT05937230 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Diabetic Patients With De Novo Native Coronary Artery Lesions
NCT00495898 ·Status: COMPLETED ·Phase: PHASE4
-
A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China
NCT03736226 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)
NCT01515228 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of RESOLUTE Zotarolimus-Eluting Stent in Treatment of Chinese Diabetic Coronary Lesions
NCT01747356 ·Status: COMPLETED ·Phase: NA
-
China Resolute Integrity 34/38 mm Study
NCT03118531 ·Status: COMPLETED ·Phase: NA
-
Study on Absorbable Zinc Alloy Drug Eluting Coronary Stent System
NCT05477940 ·Status: UNKNOWN ·Phase: NA
-
Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
NCT02452736 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis
NCT03373695 ·Status: COMPLETED ·Phase: NA
-
SYNERGY China: Assess SYNERGY Stent in China
NCT02499692 ·Status: COMPLETED ·Phase: NA
-
Sirolimus-Eluting Stent Versus Standard Stent in Diabetic
NCT00755443 ·Status: COMPLETED ·Phase: PHASE4
-
Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients
NCT01710748 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in Diabetes
NCT01257373 ·Status: UNKNOWN
-
Prospective Assessment of Efficacy and Safety of Drug Eluting Stents
NCT02313038 ·Status: COMPLETED
-
Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for Coronary Small Vessels
NCT06345209 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Safety and Performance Assessment of Drug-Eluting Stent CRE8 in Diabetic Patients
NCT03842813 ·Status: UNKNOWN
-
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
NCT01249027 ·Status: COMPLETED
-
The Study to Compare Cypher Versus Cypher Select in Treating Cornary Artery Lesions.
NCT00232791 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
HELIOS China Registry: Evaluation of the HELIOS Stent in a 'Real-World' Patient Population
NCT03916432 ·Status: RECRUITING ·Phase: NA